Friday, May 31, 2024
Tetra Pharm Technologies and Kvantify have formed a strategic partnership to accelerate the discovery and development of drug candidates targeting the endocannabinoid system (ECS).
Tetra Pharm Technologies, expressed pride in the collaboration, highlighting their shared commitment to scientific solutions. He believes this partnership will speed up drug development and expand their pipeline of candidates for 2024.
This collaboration aims to revolutionize ECS-targeted drug discovery, potentially advancing patient care significantly.
The partners will explore endocannabinoid receptors and their interactions with Tetra Pharm Technologies' pipeline. This approach is expected to advance the existing pipeline and uncover new discoveries.
Tetra Pharm Technologies has 11 drug candidates in its pipeline, each targeting specific receptors with unique modes of action. They aim for a distinct mode of action guided by their understanding of the endocannabinoid system.
Tetra Pharm Technologies highlighted the benefits of the Kvantify platform, which enables broader screening and effective identification of key structural attributes of drug candidates. This aids in guiding their activities, facilitating faster progression of candidates through the pipeline.
The collaboration involves comprehensive screening of molecular combinations suspected of acting as ligands to endocannabinoid receptors. Kvantify's CNS module provides insight into blood-brain barrier penetration propensity.
Nils Anton Berglund, Head of Strategic Alliances at Kvantify, emphasized the potential impact of leveraging the endocannabinoid system in drug discovery, highlighting the synergy between Tetra Pharm Technologies' expertise and Kvantify's precision in computational drug discovery.
Kvantify, echoed excitement about the collaboration, emphasizing the synergistic combination of Tetra Pharm Technologies' drug delivery technology and Kvantify's computational drug discovery platform, promising more efficient development of novel drugs.
Kvantify, established in 2022, is a Danish quantum company delivering software solutions and services to address challenging problems, including biotechnology and medicine, with over 65 experts spanning various fields.
Source: prnewswire.com
